STOCK TITAN

Innate Pharma reports initial IPH4502 Phase 1 results

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(Moderate)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
6-K

Rhea-AI Filing Summary

Innate Pharma SA (IPHA) reported initial Phase 1 results for IPH4502, an investigational Nectin-4-targeting antibody-drug conjugate, from 76 patients with advanced solid tumors; the data cutoff was August 17, 2026. The study tested six dose levels from 0.6 to 3.6 mg/kg every three weeks. The maximum tolerated dose was 3.6 mg/kg, with stomatitis the only reported dose-limiting toxicity. Grade 3 or higher treatment-emergent adverse events occurred in 43.4% of patients, including anemia in 11.8%.

At the maximum tolerated dose, objective response rate was 33% (2/6) in non-urothelial tumors. In the 19-patient urothelial cohort, all previously treated with enfortumab vedotin, three partial responses (one confirmed and two unconfirmed) were reported at intermediate doses; the unconfirmed disease control rate was 68.4% [95% CI 46.0–84.6]. Innate is initiating dose optimization for second-line or later urothelial cancer after enfortumab vedotin. The study will evaluate split dosing on Days 1 and 8 of each three-week cycle with mandatory prophylaxis to help reduce stomatitis.

Filing Explained

The 6-K incorporates its report and most of the accompanying release into Innate Pharma’s existing Form F-3 and Form S-8 registration statements as of November 18, 2026, adding this disclosure to those registrations.

Phase 1 patients 76 patients Dose-escalation study in patients with advanced solid tumors
Maximum tolerated dose 3.6 mg/kg Administered once every three weeks
Objective response rate 33% (2/6) Non-urothelial tumors at the 3.6 mg/kg maximum tolerated dose
Grade 3 or higher treatment-emergent adverse events 43.4% Patients in the Phase 1 study
Grade 3 or higher anemia 11.8% Patients in the Phase 1 study
Stomatitis 27.6% overall; 3.9% Grade 3 or higher Patients in the Phase 1 study
Partial responses 3 responses Urothelial-cancer cohort at intermediate dose levels; one confirmed and two unconfirmed
Unconfirmed disease control rate 68.4% [95% CI 46.0–84.6] Urothelial-cancer cohort at intermediate dose levels
antibody-drug conjugate (ADC) medical
"Nectin-4-targeting antibody-drug conjugate (ADC)"
An antibody-drug conjugate (ADC) is a targeted medical treatment that combines an antibody, which acts like a guided missile seeking out specific cells, with a powerful drug to destroy those cells. It is designed to deliver medication directly to diseased cells, minimizing damage to healthy tissue. For investors, ADCs represent innovative therapies with potential for high growth, especially if they prove effective in treating difficult-to-cure conditions.
maximum tolerated dose medical
"maximum tolerated dose was established at 3.6 mg/kg"
Maximum tolerated dose is the highest amount of a substance, such as a medication or chemical, that can be used without causing unacceptable side effects or harm. It’s like finding the maximum speed you can drive without risking a ticket or accident. For investors, understanding this concept helps gauge how much risk or exposure is safe or sustainable in a given situation.
dose-limiting toxicity medical
"stomatitis as the only reported dose-limiting toxicity"
Dose-limiting toxicity is a serious, treatment-related side effect observed in clinical trials that prevents researchers from safely increasing a drug’s dose. It matters to investors because these toxic effects set the maximum tolerated dose, influence whether a drug can reach levels that are effective, and therefore affect development timelines, costs, and the chance of regulatory approval — like a safety speed limit on how far a drug program can go.
objective response rate (ORR) medical
"objective response rate (ORR) of 33% (2/6)"
The objective response rate (ORR) is the percentage of patients in a clinical trial whose tumors shrink by a pre-set amount for a minimum time, counting both complete disappearance and meaningful partial shrinkage. Investors watch ORR because it gives an early, quantitative signal that a treatment is having a direct effect on disease—like the percent of people whose fever drops after taking a medicine—which can influence expectations for later trial success, regulatory approval, and market potential.
RECIST v1.1 medical
"measured using RECIST v1.1 criteria"
RECIST v1.1 is a standardized set of rules used in cancer trials to measure how solid tumors change over time, defining when tumors shrink, grow, or stay the same based on imaging scans. Investors care because these consistent measurements determine key trial results and regulatory decisions—like whether a drug is seen as effective—so RECIST-based outcomes directly affect a therapy’s approval prospects, market potential, and company valuation.
unconfirmed disease control rate medical
"unconfirmed disease control rate [95%CI] was 68.4%"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What objective response rate did IPHA report for IPH4502 at the maximum tolerated dose?

IPH4502 had an objective response rate of 33% (2/6) at 3.6 mg/kg, the maximum tolerated dose administered once every three weeks, among patients with non-urothelial tumors. Results were as of August 17, 2026.

What did IPHA report for IPH4502 in urothelial cancer after enfortumab vedotin?

All 19 urothelial-cancer patients had previously received enfortumab vedotin. At intermediate doses, three partial responses were observed (one confirmed and two unconfirmed), and the unconfirmed disease control rate was 68.4% [95% CI 46.0–84.6]; none of the 19 patients received 3.6 mg/kg.

What safety findings did IPHA report for IPH4502?

Stomatitis was the only reported dose-limiting toxicity, and no febrile neutropenia, hematologic dose-limiting toxicities, or peripheral-neuropathy signal was reported. Grade 3 or higher treatment-emergent adverse events occurred in 43.4% of patients, including anemia in 11.8%; stomatitis occurred in 27.6%, including 3.9% Grade 3 or higher.

What is planned next for IPH4502?

Innate is initiating Phase 1 dose optimization in second-line or later urothelial cancer after enfortumab vedotin. The study will evaluate split dosing on Days 1 and 8 of each three-week cycle with mandatory prophylaxis to help reduce stomatitis and inform a recommended Phase 2 dose and schedule; the first patient is planned in the first half of 2027.

Is IPH4502 approved or available for commercial use?

IPH4502 remains under clinical development and has not received marketing authorization in the European Union or approval from the U.S. Food and Drug Administration. Its safety and efficacy have not been established for commercial use, and the product is not available for commercial distribution.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934

Date of report: November 18, 2026
Commission File Number: 001-39084
Innate Pharma S.A.
(Translation of registrant's name into English)

Innate Pharma S.A.
117 Avenue de Luminy—BP 30191
13009 Marseille, France
+ 33 (0) 4 30 30 30
(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F [ X ]    Form 40-F [ ]









INCORPORATION BY REFERENCE

This Report on Form 6-K and Exhibit 99.1 to this Report on Form 6-K (excluding the quote from Jonathan Dickinson, Chief Executive Officer of the Company, on page 1, references to webcasts on the third page, the related Internet links, addresses, and attendance details, and the contact details on pages four and give) shall be deemed to be incorporated by reference into the registration statement on Form F-3 (File No. 333-276164) and registration statement on Form S-8 (File No. 333 282031) of Innate Pharma S.A. (including any prospectuses forming a part of such registration statements) and to be a part thereof from the date on which this report is furnished, to the extent not superseded by documents or reports subsequently filed or furnished.

















EXHIBIT INDEX

Exhibit    Description

99.1     Press Release dated November 18, 2026






















































SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

INNATE PHARMA S.A.


Date: November 18, 2026    By:    /s/ JONATHAN DICKINSON     Name:    Jonathan Dickinson
Title:    Chief Executive Officer










































EXHIBIT 99.1


Innate Pharma presents initial Phase 1 clinical data for IPH4502 at ENA 2026

•Encouraging tolerability profile with stomatitis as the only dose-limiting toxicity; low overall hematologic toxicity, consistent with low circulating free-exatecan levels, supporting linker stability
•Antitumor activity observed across tumor types, including in post-enfortumab vedotin urothelial cancer; ORR of 33% (2/6) at the maximum tolerated dose of 3.6 mg/kg Q3W in non-urothelial tumors
•Initiating dose optimization with first patient planned in H1 2027, to further characterize safety and activity in post-EV urothelial cancer at upper dose levels and define a recommended Phase 2 dose and schedule
•Following the poster presentation at ENA (poster), Innate will host an in-person and virtual key opinion leader (KOL) event focused on IPH4502, today at 11:00 a.m. ET / 4:00 p.m. GMT (webcast link)

Marseille, France, November 18, 2026, 7:00 A.M. CET

Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announced initial Phase 1 data from its ongoing study of IPH4502, an investigational Nectin-4-targeting antibody-drug conjugate (ADC) incorporating an exatecan payload, in patients with advanced solid tumors. The results are being presented today at the 38th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics (ENA 2026).

“The Phase 1 findings provide an encouraging foundation for the continued development of IPH4502,” said Jonathan Dickinson, Chief Executive Officer of Innate Pharma. “The observed antitumor activity and safety profile strengthen our commitment to advancing this program, particularly for patients with urothelial cancer previously treated with enfortumab vedotin, where significant unmet need remains. Our focus now is on optimizing the dose and schedule to further characterize antitumor activity and tolerability in this setting and inform selection of a recommended Phase 2 regimen.”

Study Population and Background
The Phase 1 dose-escalation study of IPH4502 enrolled 76 patients with advanced solid tumors across six dose levels ranging from 0.6 mg/kg to 3.6 mg/kg, administered once every three weeks. Patients were heavily pretreated, with a median of 3.5 prior lines of systemic therapy and represented more than 10 tumor types. Nineteen patients had urothelial cancer (UC), all of whom had previously received PADCEV® (enfortumab vedotin). The primary objective of the study was to assess the safety and tolerability of IPH4502, while secondary objectives include evaluating its pharmacokinetics and antitumor activity in patients with advanced solid tumors.

Safety and Tolerability
As of the August 17, 2026 data cutoff, IPH4502 was well-tolerated during Phase 1 dose escalation, with low overall hematologic toxicity.

•The maximum tolerated dose was established at 3.6 mg/kg administered once every three weeks, with stomatitis as the only reported dose-limiting toxicity. No febrile neutropenia or hematologic dose-limiting toxicities were reported, and no signal of peripheral neuropathy was observed.
•Grade 3 or higher treatment-emergent adverse events (TEAEs) were reported in 43.4% of patients, including Grade 3 or higher anemia in 11.8%. Stomatitis occurred in 27.6% of patients overall, including 3.9% with Grade 3 or higher events.
•TEAEs led to dose reductions in 7.9% of patients and treatment discontinuations in 5.3%.
Antitumor Activity
As of the August 17, 2026 data cutoff, antitumor activity (measured using RECIST v1.1 criteria) was observed across multiple dose levels, tumor types and Nectin-4 expression levels.

•Objective responses were observed in patients in several tumor types and across low, moderate and high Nectin-4 expression levels.
•At the maximum tolerated dose of 3.6 mg/kg, an objective response rate (ORR) of 33% (2/6)[1] was observed in patients with non-urothelial tumors.
•In urothelial cancer, 19 patients were enrolled, with a median of three prior lines of systemic therapy; all had previously received enfortumab vedotin. Out of these 19 patients, 15 were enrolled at 2.4 or 2.8 mg/kg, 4 at 3.2 mg/kg and none at 3.6 mg/kg (MTD). At these intermediate dose levels, antitumor activity was observed, with 3 partial responses (1



confirmed and 2 unconfirmed partial responses) and tumor shrinkage in the majority of patients. The unconfirmed disease control rate [95%CI] was 68.4% [46.0 - 84.6].

Future Clinical Development Strategy
Phase 1 dose optimization is being initiated in second-line or later urothelial cancer following enfortumab vedotin, to further characterize safety and activity in post-EV urothelial cancer at upper dose levels. The first patient is planned in the first half of 2027. The study will evaluate split dosing on Days 1 and 8 of each three-week cycle with mandatory prophylaxis to help reduce stomatitis and inform selection of a recommended Phase 2 dose and schedule.

ENA Presentation and KOL Event
Following the Phase 1 IPH4502 data being presented at the 38th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics on November 18, 2026, Innate will host an in-person and virtual key opinion leader (KOL) event the same day, at 11:00 a.m. ET / 4:00 p.m. GMT to discuss the results, their clinical context and the planned next steps of IPH4502 development (press release). The event will take place at IET London: Savoy Place, with a live webcast available through the following registration link: https://lifescievents.com/event/inz37gy.

About IPH4502
IPH4502 is Innate Pharma's proprietary Nectin-4 antibody-drug conjugate (ADC), built on three differentiated components. The payload is exatecan, a potent topoisomerase I inhibitor, with the potential to overcome key limitations associated with monomethyl auristatin E (MMAE)-based ADCs, including multidrug resistance protein 1 (MDR1)-mediated resistance. IPH4502 incorporates a proprietary stable linker designed to slow the release of free exatecan into the circulation in order to improve tolerability. The binder is a proprietary humanized anti-Nectin-4 antibody with high affinity and a distinct, non-overlapping epitope compared with enfortumab vedotin (EV). IPH4502 is currently being evaluated in the Phase 1 IPH4502-101 study (NCT06781983) in patients with advanced solid tumors known to express Nectin-4. Initial clinical data from the Dose escalation phase (ENA 2026 poster) showed antitumor activity across multiple tumor types, including urothelial cancer previously treated with enfortumab vedotin, alongside an encouraging tolerability profile with low overall hematologic toxicity. Phase 1 dose optimization is being initiated in second-line or later urothelial cancer following enfortumab vedotin.

IPH4502 is currently under clinical development and has not received marketing authorization in the European Union or approval from the U.S. Food and Drug Administration (FDA). Its safety and efficacy have not been established for any commercial use. The product is not available for commercial distribution.

About Innate Pharma:

Innate Pharma S.A. is a global, clinical-stage biotechnology company developing immunotherapies for cancer patients. Leveraging its expertise in antibody-engineering and innovative target identification, Innate Pharma is developing innovative and differentiated next-generation antibody therapeutics.
Innate Pharma is advancing a portfolio of differentiated potential first- and/or best-in-class assets, focused on areas of high unmet medical need. Its proprietary pipeline is centered on antibody-drug conjugates (ADCs), led by IPH4502, a differentiated Nectin-4 ADC in clinical development for solid tumors, and supported by a preclinical portfolio of next-generation ADC candidates. In parallel, Innate is advancing two partnered late-stage assets: lacutamab, developed with Sobi for T-cell lymphomas, and monalizumab, developed with AstraZeneca for non-small cell lung cancer (NSCLC).
Innate Pharma has established collaborations with leading biopharmaceutical companies, including Sobi, Sanofi and AstraZeneca, as well as renowned academic and research institutions, to advance innovation in immuno-oncology.
Headquartered in Marseille, France, Innate Pharma is listed on Euronext Paris and Nasdaq in the US.
Learn more about Innate Pharma at www.innate-pharma.com and follow us on LinkedIn and X.

Information about Innate Pharma shares:
ISIN code: FR0010331421
Ticker code: Euronext: IPH Nasdaq: IPHA
LEI: 9695002Y8420ZB8HJE29


Disclaimer on forward-looking information and risk factors:

This press release contains certain forward-looking statements, including those within the meaning of applicable securities laws, including the Private Securities Litigation Reform Act of 1995. The use of certain words, including “plan,” “believe,”



“can,” “could,” “estimate,” “expect,” “may,” “might,” “potential,” “should,” “will,” or the negative of these and similar expressions, is intended to identify forward-looking statements. Although Innate believes its expectations are based on reasonable assumptions, these forward-looking statements are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those anticipated. These risks and uncertainties include, among other things, the uncertainties inherent in research and development, including related to safety, progression of and results from its ongoing and planned clinical trials and preclinical studies, review and approvals by regulatory authorities of its product candidates, the Company’s reliance on third parties to manufacture its product candidates, the Company’s commercialization efforts and the Company’s continued ability to raise capital to fund its development, including the trading price and volatility of Innate’s ADSs and Ordinary Shares and risks related to Innate’s business and financial performance. For additional discussion of risks and uncertainties, please refer to the Risk Factors (“Facteurs de Risque") section of the Universal Registration Document filed with the French Financial Markets Authority (“AMF”), which is available on the AMF website http://www.amf-france.org or on Innate Pharma’s website, and public filings and reports filed with the U.S. Securities and Exchange Commission (“SEC”), including the Company’s Annual Report on Form 20-F for the year ended December 31, 2025, and subsequent filings and reports filed with the AMF or SEC, or otherwise made public by the Company. References to the Company’s website and the AMF website are included for information only and the content contained therein, or that can be accessed through them, are not incorporated by reference into, and do not constitute a part of, this press release.
This press release and the information contained herein do not constitute an offer to sell or a solicitation of an offer to buy or subscribe to shares in Innate Pharma in any country.

For additional information, please contact:

Innate Pharma
Stéphanie Cornen
stephanie.cornen@innate-pharma.fr
Investor Relations
investors@innate-pharma.fr
Medias
communication@innate-pharma.fr     


Filing Exhibits & Attachments

1 document

Keep reading